(IART) Integra LifeSciences Holdings Corporation Expects Q4 Revenue Range $413.0M - $433.0M

Integra LifeSciences (IART) anticipates Q4 2026 revenue between $413.0M and $433.0M, with full-year revenue expected to range from $1.63B to $1.65B, slightly below FactSet's estimate of $1.66B. The company reported Q3 adjusted earnings and revenue growth.

Original reporting
Published Oct 21, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The guidance is modestly below market expectations, which could trigger short-term price weakness.

02

Market read

The new revenue forecast may affect IART's stock and related healthcare sector sentiment.

03

What to watch

Potential cost reductions or new product launches not reflected in the guidance.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Integra LifeSciences (IART) provides medical devices and neurosurgical products. The company released its Q4 revenue outlook ahead of its earnings call.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences disclosed its Q4 revenue guidance of $413M-$433M, a new primary corporate forecast.

Expected impact

likely downside pressure as market prices in lower revenue expectations

Evidence & confidence

The disclosed range is below analyst estimates, prompting potential sell pressure.

Market effects

May signal softer demand in the medical device sector.

Limited to U.S. healthcare investors.

Minimal global impact.

Counterpoint

If the guidance reflects strategic investments, the stock could rebound on long-term growth.

Key entities

  • Integra LifeSciences Holdings Corporation

    US-listed medical device manufacturer.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.